×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Mintz Advises Daré Bioscience in $22M Non-Dilutive Strategic Royalty and Revenue Interest Financing
Mintz
Mintz advised Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company focused on women's health, in a $22 million non-dilutive...
1 week ago
Dare Bioscience shares target cut, maintains buy rating
Investing.com
On Thursday, Jones Trading adjusted its outlook on Dare Bioscience (NASDAQ: DARE), reducing the price target to $5.00 from the previous...
5 days ago
HC Wainwright & Co. Reiterates Dare Bioscience (DARE) Buy Recommendation
MSN
Fintel reports that on June 6, 2023, HC Wainwright & Co. reiterated coverage of Dare Bioscience (NASDAQ:DARE) with a Buy recommendation.
4 days ago
Daré Bioscience (NASDAQ:DARE) Lifted to “Buy” at Brookline Capital Management
Defense World
Read Daré Bioscience (NASDAQ:DARE) Lifted to “Buy” at Brookline Capital Management at Defense World.
3 days ago
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive ...
Yahoo Finance
Daré Bioscience's DARE-LARC1 Platform Technology has Transformative Potential for Women's Health as well as in Treating a Broad Range of...
1 month ago
Brookline Capital upgrades Dare Bioscience, cites improved funding (NASDAQ:DARE)
Seeking Alpha
Brookline Capital Markets has upgraded its rating on Dare Bioscience (DARE) to buy, citing improved funding. Read more here.
6 days ago
Dare Bioscience reports Q1 EPS (7c) vs. (9c) last year - TipRanks.com
Tipranks
Reports Q1 revenue $9302 vs. $0 last year “The progress across our portfolio in the first quarter, along with the $22 million we secured in...
6 days ago
Dare Bioscience Inc (DARE) (Q1 2024) Earnings Call Transcript Highlights: Strategic Moves Amid Financial Challenges
GuruFocus
General and Administrative Expenses: Approximately $2.7 million for Q1 2024.Research & Development Expenses: Approximately $3.3 million for...
1 week ago
Daré Bioscience launches Phase III hormone-free contraceptive trial
Clinical Trials Arena
The hormone-free contraceptive trial is set to enrol around 250 patients as the company gears up to seek FDA approval.
5 months ago
Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
WFXRtv
Development Program Highlights and Anticipated 2024 Milestones. Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal...
1 week ago